Corona Remedies Bhayla facility commences additional commercial production of medicines
Ahmedabad: Corona Remedies has announced that the Company has successfully commenced the additional commercial production of tablet(s) / capsule(s) at the Bhayla manufacturing facility of the Company.
As on March 31, 2025, the Facility has an installed capacity of 852.80 million with the available capacity of 600 million and actual production of 561.49 million which is equivalent to capacity utilization of 93.58%.
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the Facility.
"The additional commercial production will add a significant milestone in the Company’s strategic expansion to augment the upcoming market demands, enhance the in-house production capabilities and improve the supply chain agility," the company stated in a BSE filing.
The commercialized additional capacity is entirely being funded through internal accruals.
CORONA Remedies Limited, founded in 2004, is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing & marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.
CORONA manufactures products for healthcare solutions as per international quality standards in its WHO-GMP/EU GMP-certified plant. CORONA has 2 DSIR-approved R&D centres with 80+ scientist teams working on new formulation development.
Next Story